Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

How This Biotech Just Knocked Out the Champ

Longtime Private Briefing favorite AbbVie Inc. (NYSE: ABBV) should continue to be a top performer in the New Year - thanks to a one-two punch of bullish catalysts that became public just ahead of the holidays.

Best of all: These two punches delivered hammer blows to AbbVie archrival Gilead Sciences Inc. (Nasdaq: GILD).

Let's take a look ...
  1. Larry Dahl | January 5, 2015

    Put a date of origin on you recycled stories please. It's very annoying to begin reading this stuff that's more than a couple days old. Who has time to read out dated stuff?

    • (Admin) Bill Patalon | January 16, 2015

      Hi Larry …

      Thanks for the note. I always try to respond to these. But I'm not sure what you're referring to here. This Private Briefing column on AbbVie focuses on the latest developments related to its new hepatitis C drug. That's all brand-new stuff.

      If you could perhaps be more specific, we'd be glad to address your concerns. And I mean that.


      William Patalon III
      Executive Editor/Editorial Director
      Money Map Press

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK